Hsbc Holdings PLC Sells 133,103 Shares of Novo Nordisk A/S $NVO

Hsbc Holdings PLC lowered its position in shares of Novo Nordisk A/S (NYSE:NVO) by 22.5% in the 4th quarter, Holdings Channel.com reports. The fund owned 459,233 shares of the company’s stock after selling 133,103 shares during the period. Hsbc Holdings PLC’s holdings in Novo Nordisk A/S were worth $23,441,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Smith Chas P & Associates PA Cpas raised its holdings in shares of Novo Nordisk A/S by 105.3% during the 3rd quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company’s stock valued at $22,497,000 after buying an additional 207,959 shares in the last quarter. Clifford Swan Investment Counsel LLC boosted its stake in Novo Nordisk A/S by 13.7% in the third quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company’s stock worth $17,267,000 after buying an additional 37,453 shares in the last quarter. Quantbot Technologies LP purchased a new stake in Novo Nordisk A/S in the third quarter worth approximately $3,171,000. CIBC Bancorp USA Inc. bought a new position in Novo Nordisk A/S during the third quarter valued at approximately $19,519,000. Finally, Romano Brothers AND Company grew its position in Novo Nordisk A/S by 704.0% during the fourth quarter. Romano Brothers AND Company now owns 34,236 shares of the company’s stock valued at $1,742,000 after acquiring an additional 29,978 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, May 12th. Wolfe Research initiated coverage on shares of Novo Nordisk A/S in a report on Thursday, March 26th. They set a “peer perform” rating on the stock. TD Cowen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price on the stock. in a research report on Tuesday, March 10th. Weiss Ratings downgraded shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Finally, Morgan Stanley upgraded shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price target for the company in a research report on Tuesday, March 3rd. Five analysts have rated the stock with a Buy rating, seventeen have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock opened at $47.49 on Thursday. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $71.79. The business’s 50 day simple moving average is $43.48 and its two-hundred day simple moving average is $45.81. The stock has a market capitalization of $212.03 billion, a P/E ratio of 11.15, a price-to-earnings-growth ratio of 4.24 and a beta of 0.78.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The firm had revenue of $10.85 billion during the quarter. Analysts forecast that Novo Nordisk A/S will post 3.45 EPS for the current year.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: UBS said the GLP-1 obesity and diabetes market remains structurally strong, with obesity driving demand and the global market potentially reaching $130 billion to $135 billion by 2030, reinforcing a favorable backdrop for Novo Nordisk and peers. Bank sees structural strength in GLP-1 market as obesity drives demand
• Positive Sentiment: Berenberg raised its price target on NVO while keeping a Buy rating, signaling continued confidence in the company’s weight-loss leadership and the potential from the oral Wegovy launch. Is Novo Nordisk A/S (NVO) Strengthening Its Weight-Loss Leadership With Oral Wegovy Launch?
• Positive Sentiment: Novo Nordisk Foundation unveiled a EUR 60.2 million cardiometabolic research push and obesity drug incubators across Europe, which investors may view as a longer-term catalyst for innovation and pipeline strength. NVO Gains as Foundation Unveils EUR 60M Cardiometabolic Research Push
• Neutral Sentiment: Recent commentary highlighted Novo Nordisk’s strong free cash flow, dividend yield, and ongoing R&D investment, suggesting the stock still appeals to investors seeking both growth and shareholder returns. Novo Nordisk: A Strong Yield And Continued Growth
• Neutral Sentiment: Zacks’ roundup of top research reports included Novo Nordisk, but the article itself was mainly a sector overview rather than a company-specific catalyst. Top Research Reports for Shell, Novo Nordisk & SAP
• Negative Sentiment: Competition remains a key risk, with articles pointing to rival obesity programs at Pfizer and Viking Therapeutics as potential threats to Novo Nordisk’s market share and future pricing power. Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.